Iatrogenic Disorders Associated With Conventional vs. Atypical Antipsychotics

References

• Goldstein JM: The new generation of antipsychotic drugs: How atypical are they? Int J Neuropsychopharmacol 2000; 3:339–349
   Google Scholar
• Richelson E, Souder T: Binding of antipsychotic drugs to hu-man brain receptors focus on newer generation compounds. Life Sci 2000; 68:29–39
   PubMed Web of Science ®Google Scholar
• Carlsson A: Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978; 135:165–173
   PubMedGoogle Scholar
• Barnes TR, McPhillips MA: How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. Int Clin Psy-chopharmacol 1995; 10(Suppl 3):115–121
   PubMedGoogle Scholar
• Esel E, Basturk M, Saffet-Gonul A, Kula M, Tayfun-Tbran M, Yabanoglu I, Sofuoglu S: Effects of olanzapine and haloperi-dol on serum prolactin levels in male schizophrenic patients. Psychoneuroendocrinology 2001; 26:641–647
   Google Scholar
• Farde I, Nyberg S: Dosing determination for novel antipsy-chotics - a PET-based approach. Int J Psychiatry Clin Practice 1998; 2:S39–S42
   Google Scholar
• Gerlach J: The continuing problem of extrapyramidal symp-toms: Strategies for avoidance and effective treatment. J Clin Psychiatry 1999; 60:20–24
   PubMedGoogle Scholar
• Casey DE, Keepers GA: Neuroleptic side effects: Acute ex-trapyramidal syndromes and tardive dyskinesia. Psychophar-macol Ser 1988; 5:74–93
   PubMedGoogle Scholar
• Adler LA, Angrist B, Reiter S, Rotrosen J: Neuroleptic-induced akathisia: A review. Psychopharmacology 1989; 97: 1–11
   PubMed Web of Science ®Google Scholar
• Rubovits R, Klawans HL, Jr: Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskine-sias. Arch Gen Psychiatry 1972; 27:502–507
   Google Scholar
• Caligiuri MP, Lacro JP, Rockwell E, McAdams LA, Jeste DV: Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 1997; 171:148–153
   PubMed Web of Science ®Google Scholar
• Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP: Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999; 156:309–311
   PubMed Web of Science ®Google Scholar
• Casey DE: Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 1999; 35(Suppl):S61–S66
   Google Scholar
• Marsalek M: Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000; 33(Suppl 1):14–33
   PubMed Web of Science ®Google Scholar
• Casey D: Neuroleptic-Induced Extrapyrarnidal Syndromes and Tardive Dyskinesia. Oxford, England: Blackwell; 1995
   Google Scholar
• Adnet P, Lestavel P, Krivosic-Horber R: Neuroleptic malig-nant syndrome. Br J Anaesth 2000; 85:129–135
   PubMed Web of Science ®Google Scholar
• Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH: QTc-interval abnormalities and psychotropic drug therapy in psy-chiatric patients. Lancet 2000; 355:1048–1052
   PubMed Web of Science ®Google Scholar
• Serentil. Mesoridazine besylate (Serentil) prescribing infor-mation. 2000
   Google Scholar
• Buckley NA, Whyte IM, Dawson AH: Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995; 33:199–204
   PubMed Web of Science ®Google Scholar
• Warner JP, Barnes TR, Henry JA: Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 1996; 93:311–313
   PubMed Web of Science ®Google Scholar
• Bernstein JG: Psychotropic drug induced weight gain: Mecha-nisms and management. Clin Neuropharmacol 1988; 11:S194–S206
   Google Scholar
• McCreadie RG, Todd N, Livingston M, Eccleston D, Watt JA, Herrington RN, Tait D, Crocket G, Mitchell MJ, Huitfeldt B: A double-blind comparative study of remoxipride and thior-idazine in the acute phase of schizophrenia. Acta Psychiatr Scand Suppl 1990; 358:136–137
   Google Scholar
• Allison DB, Mentore JL, Hen M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999; 156:1686–1696
   PubMed Web of Science ®Google Scholar
• Casey DE, Zorn SH: The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 2001; 62:4–10
   PubMed Web of Science ®Google Scholar
• Larrey D, Erlinger S: Drug-induced cholestasis. Baillieres Clin Gastroenterol 1988; 2:423–452
   Google Scholar
• Petty RG: Prolactin and antipsychotic medications: Mecha-nism of action. Schizophr Res 1999; 35(Suppl):S67–S73
   Google Scholar
• Dickson RA, Seeman MV, Corenblum B: Hormonal side ef-fects in women: Typical versus atypical antipsychotic treat-ment. J Clin Psychiatry 2000; 61:10–15
   PubMed Web of Science ®Google Scholar
• Yasuhara T, Nishida K, Uchida K, Tani N, Machida T, Kinoshita S: Corneal endothelial changes in schizophrenic patients with long-term administration of major tranquilizers. Am J Ophthalmol 1996; 121:84–88
   Google Scholar
• Smith D, Pantelis C, McGrath J, Tangas C, Copolov D: Ocular abnormalities in chronic schizophrenia: Clinical implications. Aust N Z J Psychiatry 1997; 31:252–256
   PubMed Web of Science ®Google Scholar
• McCarty CA, Wood CA, Fu CL, Livingston PM, Mackersey S, Stanislavsky Y, Taylor HR: Schizophrenia, psychotropic medication, and cataract. Ophthalmology 1999; 106:683–687
   Google Scholar
• Harth Y, Rapoport M: Photosensitivity associated with an-tipsychotics, antidepressants and anxiolytics. Drug Saf 1996; 14:252–259
   PubMed Web of Science ®Google Scholar
• Wolf ME, Richer S, Berk MA, Mosnaim AD: Cutaneous and ocular changes associated with the use of chlorpromazine. lot J Clin Pharmacol Ther Toxicol 1993; 31:365–367
   PubMedGoogle Scholar
• Jibson MD, Tandon R: New atypical antipsychotic medica-tions. J Psychiatr Res 1998; 32:215–228
   PubMed Web of Science ®Google Scholar
• Bhana N, Foster RH, Olney R, Plosker GL: Olanzapine: An updated review of its use in the management of schizophrenia. Drugs 2001; 61:111–161
   PubMed Web of Science ®Google Scholar
• Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J: Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22:254–258
   PubMedGoogle Scholar
• Lieberman J: Clozapine: Clinical evidence of novel effects. Clin Neuropharmacol 1986; 9:140–141
   Google Scholar
• Peuskens J, Group RS: Risperidone in the treatment of pa-tients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166:712–733
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG: Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizo-phrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42:233–246
   Google Scholar
• Tran PV, Dellva MA, Tollefson GD, Beasley CM, Jr, Potvin JH, Kiesler GM: Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia [published erratum appears in J Clin Psy-chiatry 1997 Jun:58(6):275]. J Clin Psychiatry 1997; 58:205–211
   Web of Science ®Google Scholar
• Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M: Comparison of risperidone and placebo for psy-chosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60:107–115
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozap-Me and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997; 337:809–815
   Google Scholar
• Heck AH, Haffmans PM, de Groot IW, Hoencamp E: Risperi-done versus haloperidol in psychotic patients with disturb-ing neuroleptic-induced extrapyramidal symptoms: A double-blind, multi-center trial. Schizophr Res 2000; 46:97–105
   PubMed Web of Science ®Google Scholar
• Ishigooka J, Inada T, Miura S: Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the Japan multicenter, double-blind olanzapine trial. Psy-chiatry Clin Neurosci 2001; 55:403–414
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S: 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psy-chiatry 1998; 155:921–928
   PubMed Web of Science ®Google Scholar
• Nyberg S, Eriksson B, Oxenstiema G, Halldin C, Farde L: Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999; 156:869–875
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of quetiap-Me in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occu-pancy. Arch Gen Psychiatry 2000; 57:553–559
   PubMed Web of Science ®Google Scholar
• Nyberg S. Nakashima Y, Nordstrom AL, Halldin C, Farde L: Positron emission tomography of in-vivo binding characteris-tics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychi-atry Supp11996; 40–44
   Google Scholar
• Seeman P, Tallerico T: Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low re-ceptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999; 156:876–884
   PubMed Web of Science ®Google Scholar
• Paulsen JS, Caligiuri MP, Palmer B, McAdams LA, Jeste DV: Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: A prospective longitudinal study. Psychophar-macology (Berl) 1996; 123:307–314
   PubMed Web of Science ®Google Scholar
• Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ, Blank K, Koblenzer J, Kahaner K: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266:2402–2406
   PubMed Web of Science ®Google Scholar
• Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A, Fell RL, McAdams LA: Risk of tar-dive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52:756–765
   PubMed Web of Science ®Google Scholar
• Woemer MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM: Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. Am J Psychiatry 1998; 155:1521–1528
   Google Scholar
• Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, Tollefson GD: Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23–30
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley CM, Jr, Tamura RN, Tran PV, Potvin HI: Blind, controlled, long-term study of the compara-tive incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154:1248–1254
   PubMed Web of Science ®Google Scholar
• Jeste DV: Tardive dyskinesia in older patients. J Clin Psychiatry 2000; 61:27–32
   PubMed Web of Science ®Google Scholar
• Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW: Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000; 22:1068–1084
   PubMed Web of Science ®Google Scholar
• Solomon CO. Manson JE: Obesity and mortality: A review of the epidemiologic data. Am J Clin Nutr 1997; 66:1044S–1050S
   Google Scholar
• Clinical guidelines on the identification, evaluation,, and treat-ment of excess body weight and obesity in adults: Executive summary. 2001
   Google Scholar
• Kurzthaler I, Fleischhacker WW: The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001; 62: 32–37
   PubMed Web of Science ®Google Scholar
• Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischacker WW: Weight gain induced by clozapine. Eur Neu-ropsychopharmacol 1995; 5:437–440
   PubMed Web of Science ®Google Scholar
• Green B: Focus on olanzapine. Curr Med Res Opin 1999; 15:79–85
   PubMed Web of Science ®Google Scholar
• Melkersson KI, Hulling AL, Brismar KE: Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61:742–749
   PubMed Web of Science ®Google Scholar
• McIntyre RS, McCann SM, Kennedy SH: Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46:273–281
   PubMed Web of Science ®Google Scholar
• Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825–835
   PubMed Web of Science ®Google Scholar
• Devinsky 0, Honigfeld G, Patin J: Clozapine-related seizures. Neurology 1991; 41:369–371
   PubMed Web of Science ®Google Scholar
• Miller DD: Review and management of clozapine side effects. J Clin Psychiatry 2000; 61:14–19
   PubMed Web of Science ®Google Scholar
• SanfilippoJS: Implications of not treating hyperprolactinemia.J Reprod Med 1999; 44:1111–1115
   Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG: Que-tiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54:549–557
   PubMed Web of Science ®Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, Jones AM: A compari-son of the effects of quetiapine Cseroquen and haloperidol in schizophrenic patients with a history of and a demon-strated, partial response to conventional antipsychotic treat-ment. PRIZE Study Group. Int Clin Psychopharmacol 2000; 15:121–131
   PubMed Web of Science ®Google Scholar
• Crawford AM, Beasley CM, Tollefson GD: The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997; 26:41–54
   PubMed Web of Science ®Google Scholar
• Conley RR, Meltzer HY: Adverse events related to olanzap-Me. J Clin Psychiatry 2000; 61:26–30
   PubMedGoogle Scholar
• Conley RR: Risperidone side effects. J Clin Psychiatry 2000; 61:20–25
   PubMedGoogle Scholar
• Kearns AE, Goff DC, Hayden DL, Daniels GH: Risperidone-associated hyperprolactinemia. Endocr Pract 2000; 6:425–429
   PubMedGoogle Scholar
• Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Jr, Tollefson GD: Double-blind comparison of olan- zapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17:407–418
   PubMed Web of Science ®Google Scholar
• Bench CJ, Lammertsma AA, Grasby PM, Dolan RI, Warringston SJ, Boyce M, Gunn KP, Brannick LY, Frackowiak RS: The time course of binding to striatal dopamine D2 recep-tors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology (Berl) 1996; 124:141–147
   Google Scholar
• Mir S, Taylor D: Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16:63–73
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC: Novel antipsychotics and new onset diabetes. Biol Psy-chiatry 1998; 44:778–783
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC: Clozapine, dia-betes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157:975–981
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ: HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47:945–948
   PubMed Web of Science ®Google Scholar
• Welch R, Chue P: Antipsychotic agents and QT changes. J Psychiatry Neurosci 2000; 25:154–160
   PubMed Web of Science ®Google Scholar
• Czekalla J, Beasley CM, Jr, Dellva MA, Berg PH, Grundy S: Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psy-chiatry 2001; 62:191–198
   Google Scholar
• Hinze-Selch D, Becker EW, Stein G, Schreiber W, Pollmacher T: Clozapine-induced parotitis: An immunologi-cal cause? Am J Psychiatry 1996; 153:840
   Google Scholar
• Drew L, Herdson P: Clozapine and constipation: A serious issue. Aust N Z J Psychiatry 1997; 31:149–150
   PubMed Web of Science ®Google Scholar
• Beasley CM, Jr, Tollefson GD, Tran PV: Safety of olanzapine. J Clin Psychiatry 1997; 58:13–17
   PubMed Web of Science ®Google Scholar
• Keck P, Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial. Psychopharma-cology (Berl) 1998; 140:173–184
   PubMed Web of Science ®Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20:491–505
   PubMed Web of Science ®Google Scholar
• Seroquel Product Package Insert. 1997
   Google Scholar
• Elias TJ, Bannister KM, Clarkson AR, Faull D, Faull RJ: Clozapine-induced acute interstitial nephritis. Lancet 1999; 354:1180–1181
   PubMed Web of Science ®Google Scholar
• Raz A, Bergman R, Eilam 0, Yungerman T, Hayek T: A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001; 321:156–158
   PubMed Web of Science ®Google Scholar